Taxanes and other microtubule stabilising agents

Bibliography

• WANT MC, TAYLOR HL, WALL ME: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifo-lia. J. Am. Chem. Soc. (1971) 93:2325–2327.
   Google Scholar
• KAYE SB, PICCART M, AAPRO M, FRANCIS P, KAVANAGHJ: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur. J. Cancer (1997) 33:2167–2170.
   PubMed Web of Science ®Google Scholar
• SCHIFF PB, FANT J, HORWITZ SB: Promotion of microtu-bule assembly in vitro by taxol. Nature (1979) 277:665–667.
   PubMed Web of Science ®Google Scholar
• KINGSTON DGI: The chemistry of Taxol. Pharm. Ther. (1991) 52:1-34. of the structure and chemistry of paclitaxel andthe synthesis from baccatin III.
   Google Scholar
• SLICHENMYER WJ, VON HOFF DD: Taxol: a new and ef-fective anti-cancer drug. Anticancer Drugs (1991) 2:519–530.
   PubMed Web of Science ®Google Scholar
• NICOLAOU KC, YANG Z, LIU JJ et al: Total synthesis of taxol. Nature (1994) 367:630–634.
   PubMed Web of Science ®Google Scholar
• ••An important breakthrough in taxane research.
   Google Scholar
• ROWINSKY EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev. Med. (1997) 48:353-374. article that discusses the clinical effectiveness andtoxicity of paclitaxel and docetaxel.
   Google Scholar
• VON HOFF DD: The taxoids: same roots, different drugs. Semin. Oncol. (1997) 24:S13.3–513.9.
   Google Scholar
• HORTOBAGYI GN: Introduction: taxoids and the man-agement of breast cancer. Semin. Oncol (1997) 24:S13.1–513.2.
   Google Scholar
• CLEMONS M, LEAHY M, VALLE J, JAYSON G, RANSON M, HOWELL A: Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer (1997) 33:2183–2193.
   PubMed Web of Science ®Google Scholar
• WEISS RB, DONEHOWER RC, WIERNIK PH et al: Hyper-sensitivity reactions from Taxol. j Clin. Oncol. (1990) 8:1263–1268.
   PubMed Web of Science ®Google Scholar
• LORENZ LA, REIMANN H-J, SCHMAL A et al: Histamine release in dogs by Cremophor El and its derivatives: oxyethylated oleic acid is the most effective constitu-ent. Agents Actions (1977) 7:63–67.
   Google Scholar
• MAIER-LENZ H, HAUNS B, HAERING B et al: Phase I study of paclitaxel administered as a 1-hour infusion: toxic-ity and pharmacokinetics. Semin. Oncol (1997) 24:S19.16–S19.19.
   Google Scholar
• PAREKH H, SIMPKINS H: The transport and binding of Taxol. Gen. Pharmacol. (1997) 29:167–172.
   Google Scholar
• SANTONI-RUGIU E, SILVERMAN JA: Functional charac-terization of the rat mdrlb encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis (1997) 18:2255–2263.
   Google Scholar
• JORDAN MA, WILSON L: Microtubules and actin fila-ments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. (1998) 10:123–130.
   PubMed Web of Science ®Google Scholar
• NOGALES E, WOLF SG, DOWNING KH: Structure of the cc,0 tubulin dimer by electron crystallography. Nature (1998) 391:199–203.
   PubMed Web of Science ®Google Scholar
• ••The atomic model of assembled tubulin. The structureshows the three domains of tubulin and the paclitaxel bind-ing site.
   Google Scholar
• DOWNING KH, NOGALES E: Tubulin and microtubule structure. Curr. Opin. Cell Biol. (1998) 10:16–22.
   PubMed Web of Science ®Google Scholar
• KOWALSKI RJ, GIANNAKAKOU P, GUNASEKERA SP et at: The microtubule-stabilising agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nuclea-tion reactions more potently than paclitaxel, and in-hibits the growth of paclitaxel-resistant cells. Mot. Pharmacol. (1997) 52:613–622.
   PubMed Web of Science ®Google Scholar
• LU Q, LUDUENA RF: Removal of III isotype enhances Taxol induced microtubule assembly. Cell Struct. Puna (1993) 18:173–182.
   PubMed Web of Science ®Google Scholar
• ••The authors show the influence of tubulin isotope composi-tion on paclitaxel induced tubulin polymerisation.
   Google Scholar
• KAVALLARIS M, KUO DY-S, BURKHART CA et al.: Taxol-resistant epithelial ovarian tumors are associated with althered expression of specific p-tubulin isotypes. Clin. Invest. (1997) 100:1282–1293.
   Google Scholar
• •Different expression of tubulin isotypes can lead to resis-tance against paclitaxel. Next to multi-drug resistance, this is another mechanism that can result in therapy failure.
   Google Scholar
• RANGANATHAN S, BENETATOS CA, COLARUSSO PJ, DEX-TER DW, HUDES HD: Altered 0-tubulin isotype expres-sion in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer (1998) 77:562–566.
   PubMed Web of Science ®Google Scholar
• MATHEW AE, MEJILLANO MR, NATH JP, HIMES RH, STELLA VJ: Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitu-mor activity. J Med. Chem. (1992) 35:145–151.
   PubMed Web of Science ®Google Scholar
• GUÉRITTE-VOEGELEIN F, GURNARD D, LAVELLE F, LE GOFF M-T, MANGATAL L, POTIER P: Relationships be-tween the structure of taxol analogues and their anti-mitotic activity. J. Med. Chem. (1991) 34:992–998.
   PubMed Web of Science ®Google Scholar
• •Structure activity study of paclitaxel analogues and the dis-covery of docetaxel.
   Google Scholar
• MOYNA G, WILLIAMS HJ, SCOTT Al: Conformational studies of paclitaxel analogs modified at the C-2' posi-tion in hydrophobic and hydrophylic solvent systems. J. Med. Chem. (1997) 40:3305–3311.
   Google Scholar
• MELTON RG, SHERWOOD RF: Antibody-enzyme conju-gates for cancer therapy. J. Natl. Cancer. Inst. (1996) 88:153–165.
   PubMed Web of Science ®Google Scholar
• •Review article that discusses antibody-directed enzyme prodrug therapy. This is a relatively novel approach to con-vert prodrugs into cytotoxic agents with increased topical specificity.
   Google Scholar
• GREENWALD RB, GILBERT CW, PENDRI A, CONOVER CD, J, MARTINEZ A: Drug delivery systems: water solu-ble Taxol 2'-poly(ethylene glycol) ester prodrugs- de-sign and in vivo effectiveness. J Med. Chem. (1996) 39:424–431.
   PubMed Web of Science ®Google Scholar
• •In depth discussion of the improved solubility and biologi-cal activity of the paclitaxel analogues disclosed in [110].
   Google Scholar
• JOHNSON RA, DOBROWOLKSKI PJ, NIDY EG et al.: 12,13-Isotaxanes: synthesis of new potent analogs and x-ray crystallographic confirmation of structure. J. Med. Chem. (1997) 40:2810–2812.
   Google Scholar
• BOLLAG DM, MCQUENEY PA, ZHU J et al.: Epothilones, anew class of microtubule-stablizing agents with a Taxol-like mechanism of action. Cancer Res. (1995) 55:2325–2333.
   PubMed Web of Science ®Google Scholar
• •Epothilones is the first new class of compounds since tax-anes that stabilise microtubules and compete with paclitaxel for the same binding site.
   Google Scholar
• TER HAAR E, KOWALSKI RJ, HAMEL E et al.: Discoder-, a cytotoxic marine agent that stabilizes micro-tubules more potently than taxol. Biochemistry (1996) 35:243–250.
   PubMed Web of Science ®Google Scholar
• •The discovery of discodermolide as a microtubule depolym-erisation inhibitor. Discodermolide induces tubulin assem-bly more efficiently than paclitaxel.
   Google Scholar
• KOWALSKI RJ, GIANNAKAKOU P, HAMEL E: Activities ofthe microtubule-stabilising agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J. Biol. Chem. (1997) 272:2534–2541.
   PubMed Web of Science ®Google Scholar
• SACKETT DL, GIANNAKAKOU P, PORUCHYNSKY M, FOJO A: Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents. Cancer Che-mother. Pharmacol (1997) 40:228–232.
   Google Scholar
• LONGLEY RE, GUNASEKERA SP, FAHERTY D, MCLANE J, DUMONT F: Immunosuppression by discodermolide. Ann. NY Acad. Sci. (1993) 696:94–107.
   Google Scholar
• HUNG DT, CHEN J, SCHREIBER SL: (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubu-lin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol. (1996) 3:287–293.
   PubMedGoogle Scholar
• BALACHANDRAN R, TER HAAR E, WELSH MJ, GRANT SG,DAY BW: The potent microtubule-stabilising agent (+)-discodermolide induces apoptosis in human breast carcinoma cells - preliminary comparisons to paclitaxel. AntiCancer Drugs (1998) 9:67–76.
   Google Scholar
• LINDEL T, JENSEN PR, FENICAL W et al.: Eleutherobin, anew cytotoxin that mimics paclitaxel (Taxol) by stabi-lising microtubules. J. Am. Chem. Soc. (1997) 119:8744–8745.
   Web of Science ®Google Scholar
• •Another new compound, structurally different from pacli-taxel, that stabilises microtubules.
   Google Scholar